Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-093 in Moderate to Severe Uveitis
NCT00444743Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Feb 2007
- Primary completion
- Nov 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human alpha-fetoprotein in uveitis, sponsored by Merrimack Pharmaceuticals. Started Feb 2007; status: completed.
02
Drugs
recombinant human alpha-fetoprotein
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT00444743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00444743.